查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496020

全球研究抗体市场：2024-2029 年预测

Global Research Antibodies Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年研究抗体市值为41.12亿美元，预计在预测期内复合年增长率为7.12%，到2029年市场总合规模达到66.53亿美元。

研究抗体一词是指一种用于多种研究目的的蛋白质，包括诊断和有用的研究和发现。由于它们能够结合特定的原子突变，这些蛋白质被用于细胞研究和开发，以限制和识别特定的细胞。透过蛋白质研究，人们已经能够评估蛋白质在细胞内如何连接以及它们如何发挥作用。

如今，抗体是研究细胞内蛋白质功能最重要的工具之一。亨廷顿氏症、多发性硬化症和帕金森氏症等神经退化性疾病正在推动神经生物学领域的研究。随着人口老化和药物变得稀缺，对研究抗体的需求变得更大。

个人化治疗方法的开发、治疗方法的进步以及新颖且可行的治疗方法的开发等技术正在比以往任何时候都得到更广泛的探索。根据联合国发布的《2019年世界人口展望》讯息，未来30年世界人口将翻一番，从2019年的77亿增至97亿，同时世界人口老化加速。 65 岁及以上人口数量将从 2019 年的十分之一（9%）增加到 2050 年的六分之一（16%）。

许多因素正在影响研究抗体市场。例子包括对基因组研究和发现的兴趣增加、提高研究可重复性的更高品质的抗体以及生命科学行业研发活动的活性化。在自订剂量和基于结构的剂量方案需求不断增长的推动下，全球研究抗体产业预计将在预测期内快速成长。

市场驱动因素：

  • 研究和开发的增加预计将推动研究抗体市场的成长。

许多生物製药和製药公司研发的显着增加主要推动了市场的成长。预计利用研究抗体获得创新的先进诊断和治疗产品将推动市场快速扩张。例如，2023 年 12 月，艾伯维 (AbbVie) 和 BigHat Biosciences 宣布合作开发肿瘤学和神经科学领域的下一代治疗抗体。 BigHat 利用该公司的 Milliner(TM) 阶段、机器学习技术平台套件和高速湿实验室来指导规划以及针对众多修復治疗目标的高品质抗体的确定。此外，2023年12月，工业株式会社将与EVQLV, INC.合作，利用EVQLV的人工智慧抗体设计引擎开发创新抗体医药品。此次合作的目的是针对小野製药选定的多个标靶创造新的抗体，并改善创新抗体医药品。此次合作也旨在提高工业产品的品质和熟练度。

预计支持产业扩张的另一个数字是政府机构对蛋白质体学和基因组学研究的资助增加。在创新基因组技术的帮助下，人们逐渐认识到导致全球死亡主要原因的遗传变数。

2024 年 2 月，研究人员从 NIH 精准医学资料中发现了超过 2.75 亿个新发现，这些数据源自于美国卫生研究院「我们所有人」研究计画的 25 万名参与者共用的资料。这些资料的一半是从具有非欧洲遗传血统的参与者获得的。这项发现为了解遗传对健康和疾病的影响提供了新途径，特别是在代表性不足的社区。预计此类市场开拓将在预测期内推动研究抗体市场的成长。

市场限制因素：

  • 抗体开发是一个耗时且成本高昂的过程，可能会阻碍市场发展。

这个过程复杂且耗时，因为抗体的生产必须反映几个重要因素，例如产生抗体的抗原、其特异性、是单株多株抗体、其影响及其再现性。抗体研究和製造过程中融入了多种创新，包括反应器、层析法、过滤框架以及下游、上游和过滤阶段的介质和缓衝液。此类操作的资本投资很高，使得整个过程变得昂贵。

主要进展：

  • 2024 年 3 月 - 吉利德和 Merus 宣布合作发现新型基于抗体的特异性T 细胞接合剂。
  • 2023 年 8 月，生命科学研究工具领域的全球领导者 Abcam plc 已同意以每股 24 美元的现金价格从 Danaher Corporation 收购该公司的所有已发行股票。该证券交易所已获得 Abcam 和 Danaher 董事会的核准。 Abcam 为药物发现、生命科学研究和诊断提供高度核准的抗体、试剂、生物标记和检测检测法。
  • 2023 年 7 月 - Bio-Techne 收购 Lunaphore Technologies SA，这是一家全自动空间生物学解决方案领域的领先公司。此次收购旨在加强 Lunaphor 作为转化和临床研究市场空间生物学领导者的地位。 Lunafore 的设备组合包括 COMET(TM)。 COMET 是一个端到端平台，将组织染色、成像和影像准备步骤整合到高通量仪器中。该平台能够自动分析每个样本中的 40 种不同的空间生物标记。 Lunafore 也提供 SPYRE(TM)抗体组合套件和 HORIZON(TM) 影像分析软体。
  • 2023 年 2 月 - Charles River Laboratories International, Inc. 推出首款 ELISA套件，用于检测基于 CHO 的生物治疗药物中残留的宿主细胞蛋白。该套件实现了业界领先的 0.1 ng/mL 灵敏度和特异性以及 90% 的抗体覆盖率。 AVS Bio 开发的专有鸡免疫球蛋白 Y (IgY) 抗体由于鸟类和哺乳动物之间的系统差异而提高了灵敏度和特异性。该套件补充了 Charles River 的生技药品测试产品，使客户能够接受行业专家的测试。
  • 2022 年 10 月 - 罗氏推出 SARS-CoV-2 快速抗体测试 2.0，这是专为照护现场环境中的医护人员设计的新测试。此测试有助于识别已产生针对 SARS-CoV-2 抗体的患者，并显示过去的感染或疫苗接种情况。当无法进行实验室测试或更适合进行指尖采血取样时，此测试非常有用。医疗保健专业人员还可以检查患者的抗体状态，并确定他们是否有先前疫苗接种后残留的可检测抗体反应。正在研究该测试以寻找值得关注的新变体。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 研究抗体的全球市场：依类型

  • 介绍
  • 单株抗体 (mAb)
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 多株抗体(pAb)
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章 研究抗体的全球市场：依研究领域

  • 介绍
  • 肿瘤学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 感染疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 免疫学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 神经病学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章 全球研究抗体市场：依技术分类

  • 介绍
  • 蛋白质印迹法
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 流式细胞技术
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 酵素免疫分析法测定法 (ELISA)
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章 全球研究抗体市场：按地区划分

  • 介绍
  • 北美洲
    • 按类型
    • 按研究领域
    • 依技术
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按研究领域
    • 依技术
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按研究领域
    • 依技术
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按研究领域
    • 依技术
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按研究领域
    • 依技术
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • ProSci Incorporated
  • Thermo Fisher Scientific Inc
  • General Electric
  • Merck KGaA
  • ImmunoPrecise Antibodies Ltd
  • Johnson & Johnson Services, Inc
  • Rockland Immunochemicals, Inc.
  • ACROBiosystems
  • Bio-Rad Laboratories, Inc.
简介目录
Product Code: KSI061611694

The global research antibodies market was valued at US$4.112 billion in 2022 and is expected to grow at a CAGR of 7.12% over the forecast period to reach a total market size of US$6.653 billion by 2029.

The term "research antibody" alludes to a sort of protein that's utilized for different research purposes, such as diagnostics and certainly helpful investigation and discovery. As a result of these proteins' capability to enchain to particular atomic variations, they are utilized in cell research and development to confine and recognize particular cells. Through their research studies of proteins, people are way better able to evaluate how proteins are connected and work inside cells.

As of today, antibodies are among the foremost vital apparatuses for examining the work of proteins in cells. Neurodegenerative illnesses such as Huntington's disease, Multiple Sclerosis, and Parkinson's disorder are empowering research in the neurobiological domain. As geriatrics increase and medicines end up scarce, the need for antibodies for investigation work is additionally rising.

The techniques of creating personalized medication, advancing therapeutics, and creating novel and viable treatments are being looked for now more extensively than in previous years. As per the United Nations (UN) information on World Population Prospects for 2019, the global population in the next thirty years will become twofold what it was in 2019, from 7.7 billion to 9.7 billion, and at the same time, the world will age more quickly. The number of individuals over the age of 65 will rise from one in eleven people in 2019 (9%) to one in six by 2050 (16%).

Many factors have affected the market of research antibodies, such as the rising interest in genomics study and discovery, the enhancement of higher-quality antibodies for reproducibility in the study, as well as an increase in R&D activities in the life sciences industry. Fueled by the expanding requirement for custom-made medication and structure-based medication plans, the worldwide industry for research antibodies is anticipated to rise quickly over the forecasted period.

Market Drivers:

  • An increase in research and development is predicted to bolster the research antibodies market growth.

A significant rise in research and development by many biopharmaceutical and pharmaceutical companies is mainly fueling the market growth. The accessibility of innovatively progressed diagnostic and therapeutic items utilizing research antibodies is anticipated to fuel a quick expansion of the market. For instance, in December 2023, AbbVie and BigHat Biosciences declared a research collaboration to create next-generation therapeutic antibodies in oncology and neuroscience. BigHat utilized its Milliner(TM) stage, a suite of machine learning technologies platforms, and a high-speed wet lab to direct the plan as well as the determination of high-quality antibodies for numerous restorative therapeutic targets. Additionally, in in December 2023, Ono Pharmaceutical Co., Ltd. collaborated with EVQLV, INC., to create innovative antibody drugs by using EVQLV's AI-powered product i.e. antibody design engine. The collaboration goal was to create novel antibodies against numerous targets, chosen by Ono, for the improvement of innovative antibody drugs. The partnership also aimed to upgrade the quality and proficiency of Ono's products.

Another figure anticipated to boost industry expansion is an increment in the sum of subsidizing given by government bodies for proteomics and genomics research and investigation. With the assistance of genomic innovative technology, hereditary variables contributing to the major causes of death happening around the world are being recognized.

In February 2024, researchers identified over 275 million new genetic variants in NIH precision medicine data, sourced from data shared by 250,000 participants of the National Institutes of Health's All of Us Research Program. Half of the data comes from non-European genetic ancestry participants. This discovery offers new avenues for understanding genetic influences on health and disease, particularly in underrepresented communities. These market developments will boost the research antibody market growth in the forecast period.

Market Restraints:

  • Developing antibodies is a time-consuming and expensive process that could hamper the market.

The process could be sophisticated and time-consuming to prepare antibodies as it needs reflection of several important factors, such as the antigen against which antibodies will be created, its specificity, monoclonal or polyclonal antibody and affectability, and its reproducibility. Separated from bioreactors and chromatography tars, filtration frameworks, as well as media and buffers for the downstream, upstream, and filtration stages, an assortment of innovations are included in the antibody research production process. Capital investment is high for such operations, making the whole procedure expensive.

Key Developments:

  • March 2024- Gilead and Merus announced a research collaboration to discover novel antibody-based trispecific T-cell engagers. The collaboration is planning to utilize Merus' proprietary Triclonics stage and Gilead's oncology skills to create different preclinical research programs.
  • August 2023- Abcam plc, a global leader in life science research tools, agreed to acquire all outstanding shares of the company from Danaher Corporation for $24.00 per share in cash. The exchange was affirmed by both the Abcam and Danaher boards of directors. Abcam provides exceedingly approved antibodies, reagents, biomarkers, and measures for drug disclosure, life sciences research, and diagnostics. Abcam is getting to work as a standalone working company inside Danaher's Life Sciences fragment.
  • July 2023- Bio-Techne acquired Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. The acquisition aims to enhance Lunaphore's spatial biology leadership position in translational and clinical research markets. Lunaphore's instrument portfolio includes COMET(TM), an end-to-end platform with tissue staining, imaging, and image preprocessing steps integrated into a high-throughput instrument. The platform can analyze 40 different spatial biomarkers per sample in each automated run. Lunaphore also offers SPYRE(TM) antibody panel kits and HORIZON(TM) image analysis software.
  • February 2023- Charles River Laboratories International introduced its first ELISA Kit for detecting residual host cell proteins in CHO-based biotherapeutics. The kit achieves industry-leading sensitivity and specificity rates, reaching 0.1 ng/mL and 90% antibody coverage. The unique chicken immunoglobulin Y (IgY) antibodies, developed by AVS Bio, increase sensitivity and specificity due to phylogenetic differences between birds and mammals. The kit complements Charles River's Biologics Testing offering, allowing clients to have industry experts perform the assay.
  • October 2022- Roche introduced the SARS-CoV-2 Rapid Antibody Test 2.0, a new test designed for healthcare professionals in point-of-care settings. This test helps identify patients with developed antibodies against SARS-CoV-2, indicating prior infection or vaccination. It is useful in situations where laboratory testing is unavailable, or finger prick sampling is preferred. Healthcare professionals can also check patients' antibody status and determine if they still have detectable antibody responses from prior vaccination. The test is being investigated against new variants of concern.

Market Segmentation:

Global Research Antibodies Market is segmented and analyzed as below:

By Type

  • Monoclonal Antibodies (mAbs)
  • Polyclonal Antibodies (pAbs)

By Research Area

  • Oncology
  • Infectious Diseases
  • Immunology
  • Neurology
  • Others

By Technology

  • Western Blotting
  • Flow Cytometry
  • Enzyme-linked immunosorbent Assay (ELISA)
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL RESEARCH ANTIBODIES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Monoclonal Antibodies (mAbs)
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Polyclonal Antibodies (pAbs)
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL RESEARCH ANTIBODIES MARKET BY RESEARCH AREA

  • 6.1. Introduction
  • 6.2. Oncology
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Infectious Diseases
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Immunology
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Neurology
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL RESEARCH ANTIBODIES MARKET BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Western Blotting
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Flow Cytometry
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL RESEARCH ANTIBODIES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Research Area
    • 8.2.3. By Technology
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Research Area
    • 8.3.3. By Technology
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Research Area
    • 8.4.3. By Technology
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Research Area
    • 8.5.3. By Technology
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Research Area
    • 8.6.3. By Technology
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. ProSci Incorporated
  • 10.2. Thermo Fisher Scientific Inc
  • 10.3. General Electric
  • 10.4. Merck KGaA
  • 10.5. ImmunoPrecise Antibodies Ltd
  • 10.6. Johnson & Johnson Services, Inc
  • 10.7. Rockland Immunochemicals, Inc.
  • 10.8. ACROBiosystems
  • 10.9. Bio-Rad Laboratories, Inc.